N
MLTX icon

Natixis’s MoonLake Immunotherapeutics MLTX Stock Holding History

Natixis’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,317
Closed -$1.27M – 1142
2023
Q4 		$1.27M Buy
+20,317
New +$1.05M 0.01% 481

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Natixis's MLTX Position: Q1 2024 in Review

Natixis sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2024, closing a stake of 20,317 shares — an estimated $1.27M sold.

Natixis first reported a position in MLTX in Q4 2023 and held it in 1 quarter. The position peaked at $1.27M in Q4 2023. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • Natixis reported no remaining MoonLake Immunotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 20,317 MoonLake Immunotherapeutics shares in Q1 2024, an estimated $1.27M.
  • Natixis first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 1 quarter.
  • Natixis's MoonLake Immunotherapeutics position peaked at $1.27M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.